nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—HBA1—breast cancer	0.205	0.481	CbGaD
Mefloquine—ACHE—breast cancer	0.0734	0.172	CbGaD
Mefloquine—CYP19A1—Exemestane—breast cancer	0.0623	0.174	CbGbCtD
Mefloquine—CYP19A1—Letrozole—breast cancer	0.053	0.148	CbGbCtD
Mefloquine—CYP19A1—Anastrozole—breast cancer	0.0472	0.132	CbGbCtD
Mefloquine—CYP19A1—breast cancer	0.0432	0.102	CbGaD
Mefloquine—BCHE—breast cancer	0.0431	0.101	CbGaD
Mefloquine—CYP19A1—Raloxifene—breast cancer	0.0239	0.0665	CbGbCtD
Mefloquine—CYP2D6—breast cancer	0.0237	0.0557	CbGaD
Mefloquine—CYP3A4—breast cancer	0.0203	0.0477	CbGaD
Mefloquine—ABCB1—breast cancer	0.0169	0.0397	CbGaD
Mefloquine—ACHE—Irinotecan—breast cancer	0.0168	0.0467	CbGbCtD
Mefloquine—CYP19A1—Tamoxifen—breast cancer	0.0158	0.044	CbGbCtD
Mefloquine—CYP19A1—Paclitaxel—breast cancer	0.0123	0.0342	CbGbCtD
Mefloquine—BCHE—Irinotecan—breast cancer	0.0101	0.0281	CbGbCtD
Mefloquine—ABCB1—Toremifene—breast cancer	0.00914	0.0254	CbGbCtD
Mefloquine—CYP3A4—Exemestane—breast cancer	0.0079	0.022	CbGbCtD
Mefloquine—CYP2D6—Idarubicin—breast cancer	0.00713	0.0199	CbGbCtD
Mefloquine—CYP3A4—Letrozole—breast cancer	0.00671	0.0187	CbGbCtD
Mefloquine—ABCB1—Lapatinib—breast cancer	0.00666	0.0186	CbGbCtD
Mefloquine—CYP3A4—Anastrozole—breast cancer	0.00598	0.0167	CbGbCtD
Mefloquine—CYP3A4—Toremifene—breast cancer	0.00547	0.0152	CbGbCtD
Mefloquine—CYP3A4—Fulvestrant—breast cancer	0.00509	0.0142	CbGbCtD
Mefloquine—CYP19A1—corpus luteum—breast cancer	0.00462	0.138	CbGeAlD
Mefloquine—CYP3A4—Thiotepa—breast cancer	0.00454	0.0126	CbGbCtD
Mefloquine—CYP3A4—Ixabepilone—breast cancer	0.00415	0.0116	CbGbCtD
Mefloquine—CYP3A4—Lapatinib—breast cancer	0.00399	0.0111	CbGbCtD
Mefloquine—ABCB1—Vinorelbine—breast cancer	0.0037	0.0103	CbGbCtD
Mefloquine—CYP2D6—Vinorelbine—breast cancer	0.00348	0.0097	CbGbCtD
Mefloquine—ABCB1—Tamoxifen—breast cancer	0.00334	0.00929	CbGbCtD
Mefloquine—ABCB1—Mitoxantrone—breast cancer	0.00325	0.00907	CbGbCtD
Mefloquine—CYP2D6—Tamoxifen—breast cancer	0.00314	0.00876	CbGbCtD
Mefloquine—CYP3A4—Raloxifene—breast cancer	0.00303	0.00843	CbGbCtD
Mefloquine—ABCB1—Gemcitabine—breast cancer	0.00287	0.00801	CbGbCtD
Mefloquine—ABCB1—Paclitaxel—breast cancer	0.0026	0.00723	CbGbCtD
Mefloquine—ABCB1—Irinotecan—breast cancer	0.00256	0.00714	CbGbCtD
Mefloquine—ABCB1—Vinblastine—breast cancer	0.00228	0.00635	CbGbCtD
Mefloquine—CYP3A4—Vinorelbine—breast cancer	0.00221	0.00617	CbGbCtD
Mefloquine—CYP2D6—Vinblastine—breast cancer	0.00215	0.00598	CbGbCtD
Mefloquine—CYP3A4—Tamoxifen—breast cancer	0.002	0.00557	CbGbCtD
Mefloquine—CYP3A4—Mitoxantrone—breast cancer	0.00195	0.00543	CbGbCtD
Mefloquine—ABCB1—Docetaxel—breast cancer	0.00188	0.00523	CbGbCtD
Mefloquine—HBA2—embryo—breast cancer	0.0016	0.0479	CbGeAlD
Mefloquine—CYP3A4—Paclitaxel—breast cancer	0.00156	0.00433	CbGbCtD
Mefloquine—CYP3A4—Irinotecan—breast cancer	0.00154	0.00428	CbGbCtD
Mefloquine—ABCB1—Doxorubicin—breast cancer	0.0014	0.0039	CbGbCtD
Mefloquine—CYP3A4—Vinblastine—breast cancer	0.00136	0.0038	CbGbCtD
Mefloquine—ABCB1—Methotrexate—breast cancer	0.00136	0.00378	CbGbCtD
Mefloquine—HBA1—skin of body—breast cancer	0.00135	0.0405	CbGeAlD
Mefloquine—CYP2D6—Doxorubicin—breast cancer	0.00132	0.00367	CbGbCtD
Mefloquine—HBA2—epithelium—breast cancer	0.00131	0.0391	CbGeAlD
Mefloquine—HBA2—skin of body—breast cancer	0.00124	0.0372	CbGeAlD
Mefloquine—HBA1—adipose tissue—breast cancer	0.00115	0.0344	CbGeAlD
Mefloquine—CYP3A4—Docetaxel—breast cancer	0.00113	0.00313	CbGbCtD
Mefloquine—HBA1—female reproductive system—breast cancer	0.00106	0.0316	CbGeAlD
Mefloquine—HBA2—adipose tissue—breast cancer	0.00106	0.0316	CbGeAlD
Mefloquine—HBA1—adrenal gland—breast cancer	0.00103	0.0308	CbGeAlD
Mefloquine—HBA1—bone marrow—breast cancer	0.000998	0.0298	CbGeAlD
Mefloquine—HBA2—female reproductive system—breast cancer	0.000971	0.029	CbGeAlD
Mefloquine—HBA1—female gonad—breast cancer	0.000962	0.0288	CbGeAlD
Mefloquine—HBA2—adrenal gland—breast cancer	0.000947	0.0283	CbGeAlD
Mefloquine—HBA2—bone marrow—breast cancer	0.000917	0.0274	CbGeAlD
Mefloquine—HBA1—endocrine gland—breast cancer	0.000895	0.0267	CbGeAlD
Mefloquine—HBA2—female gonad—breast cancer	0.000883	0.0264	CbGeAlD
Mefloquine—Flecainide—CYP2D6—breast cancer	0.000855	1	CrCbGaD
Mefloquine—CYP3A4—Doxorubicin—breast cancer	0.000839	0.00234	CbGbCtD
Mefloquine—HBA2—endocrine gland—breast cancer	0.000822	0.0246	CbGeAlD
Mefloquine—HBA1—lymph node—breast cancer	0.000619	0.0185	CbGeAlD
Mefloquine—HBA2—lymph node—breast cancer	0.000568	0.017	CbGeAlD
Mefloquine—ADORA2A—female reproductive system—breast cancer	0.000505	0.0151	CbGeAlD
Mefloquine—ADORA2A—adrenal gland—breast cancer	0.000493	0.0147	CbGeAlD
Mefloquine—ADORA1—adipose tissue—breast cancer	0.000475	0.0142	CbGeAlD
Mefloquine—ADORA1—female reproductive system—breast cancer	0.000436	0.013	CbGeAlD
Mefloquine—ADORA2A—endocrine gland—breast cancer	0.000428	0.0128	CbGeAlD
Mefloquine—BCHE—nipple—breast cancer	0.000426	0.0127	CbGeAlD
Mefloquine—ACHE—adrenal gland—breast cancer	0.000423	0.0126	CbGeAlD
Mefloquine—ADORA1—endocrine gland—breast cancer	0.000369	0.011	CbGeAlD
Mefloquine—CYP19A1—endometrium—breast cancer	0.000357	0.0107	CbGeAlD
Mefloquine—CYP19A1—uterus—breast cancer	0.000329	0.00984	CbGeAlD
Mefloquine—CYP19A1—adipose tissue—breast cancer	0.000322	0.00962	CbGeAlD
Mefloquine—CYP19A1—female reproductive system—breast cancer	0.000296	0.00884	CbGeAlD
Mefloquine—CYP19A1—adrenal gland—breast cancer	0.000289	0.00863	CbGeAlD
Mefloquine—BCHE—skin of body—breast cancer	0.000273	0.00816	CbGeAlD
Mefloquine—CYP19A1—female gonad—breast cancer	0.000269	0.00805	CbGeAlD
Mefloquine—BCHE—endometrium—breast cancer	0.000257	0.00769	CbGeAlD
Mefloquine—ADORA1—lymph node—breast cancer	0.000255	0.00763	CbGeAlD
Mefloquine—ACHE—lymph node—breast cancer	0.000254	0.00758	CbGeAlD
Mefloquine—CYP19A1—endocrine gland—breast cancer	0.00025	0.00748	CbGeAlD
Mefloquine—BCHE—uterus—breast cancer	0.000237	0.00709	CbGeAlD
Mefloquine—BCHE—pituitary gland—breast cancer	0.000233	0.00696	CbGeAlD
Mefloquine—BCHE—adipose tissue—breast cancer	0.000232	0.00693	CbGeAlD
Mefloquine—BCHE—female reproductive system—breast cancer	0.000213	0.00637	CbGeAlD
Mefloquine—BCHE—adrenal gland—breast cancer	0.000208	0.00622	CbGeAlD
Mefloquine—BCHE—bone marrow—breast cancer	0.000201	0.00601	CbGeAlD
Mefloquine—BCHE—endocrine gland—breast cancer	0.00018	0.00539	CbGeAlD
Mefloquine—CYP19A1—lymph node—breast cancer	0.000173	0.00517	CbGeAlD
Mefloquine—ABCB1—embryo—breast cancer	0.000168	0.00501	CbGeAlD
Mefloquine—CYP3A4—female reproductive system—breast cancer	0.000143	0.00429	CbGeAlD
Mefloquine—CYP2D6—female reproductive system—breast cancer	0.000141	0.00422	CbGeAlD
Mefloquine—ABCB1—epithelium—breast cancer	0.000137	0.00409	CbGeAlD
Mefloquine—CYP2D6—female gonad—breast cancer	0.000128	0.00384	CbGeAlD
Mefloquine—BCHE—lymph node—breast cancer	0.000125	0.00373	CbGeAlD
Mefloquine—ABCB1—endometrium—breast cancer	0.000123	0.00366	CbGeAlD
Mefloquine—CYP3A4—endocrine gland—breast cancer	0.000121	0.00363	CbGeAlD
Mefloquine—CYP2D6—endocrine gland—breast cancer	0.000119	0.00357	CbGeAlD
Mefloquine—ABCB1—uterus—breast cancer	0.000113	0.00338	CbGeAlD
Mefloquine—ABCB1—pituitary gland—breast cancer	0.000111	0.00332	CbGeAlD
Mefloquine—ABCB1—adipose tissue—breast cancer	0.00011	0.0033	CbGeAlD
Mefloquine—ABCB1—female reproductive system—breast cancer	0.000102	0.00304	CbGeAlD
Mefloquine—ABCB1—adrenal gland—breast cancer	9.91e-05	0.00296	CbGeAlD
Mefloquine—ABCB1—bone marrow—breast cancer	9.59e-05	0.00287	CbGeAlD
Mefloquine—ABCB1—female gonad—breast cancer	9.24e-05	0.00276	CbGeAlD
Mefloquine—ABCB1—endocrine gland—breast cancer	8.6e-05	0.00257	CbGeAlD
Mefloquine—ABCB1—lymph node—breast cancer	5.94e-05	0.00178	CbGeAlD
Mefloquine—Dermatitis—Mitoxantrone—breast cancer	2.52e-05	0.00023	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Docetaxel—breast cancer	2.52e-05	0.00023	CcSEcCtD
Mefloquine—Chills—Methotrexate—breast cancer	2.52e-05	0.00023	CcSEcCtD
Mefloquine—Headache—Mitoxantrone—breast cancer	2.5e-05	0.000229	CcSEcCtD
Mefloquine—Headache—Irinotecan—breast cancer	2.5e-05	0.000229	CcSEcCtD
Mefloquine—Hypotension—Capecitabine—breast cancer	2.5e-05	0.000229	CcSEcCtD
Mefloquine—Insomnia—Docetaxel—breast cancer	2.5e-05	0.000229	CcSEcCtD
Mefloquine—Paraesthesia—Docetaxel—breast cancer	2.48e-05	0.000227	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—breast cancer	2.48e-05	0.000227	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—breast cancer	2.48e-05	0.000227	CcSEcCtD
Mefloquine—Vomiting—Gemcitabine—breast cancer	2.48e-05	0.000227	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—breast cancer	2.47e-05	0.000226	CcSEcCtD
Mefloquine—Dyspnoea—Docetaxel—breast cancer	2.46e-05	0.000225	CcSEcCtD
Mefloquine—Somnolence—Docetaxel—breast cancer	2.46e-05	0.000225	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—breast cancer	2.46e-05	0.000225	CcSEcCtD
Mefloquine—Rash—Gemcitabine—breast cancer	2.46e-05	0.000225	CcSEcCtD
Mefloquine—Dermatitis—Gemcitabine—breast cancer	2.45e-05	0.000225	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—breast cancer	2.45e-05	0.000224	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—breast cancer	2.45e-05	0.000224	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Erythema—Methotrexate—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Headache—Gemcitabine—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Capecitabine—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Flushing—Epirubicin—breast cancer	2.44e-05	0.000223	CcSEcCtD
Mefloquine—Vomiting—Fluorouracil—breast cancer	2.43e-05	0.000223	CcSEcCtD
Mefloquine—Dyspepsia—Docetaxel—breast cancer	2.43e-05	0.000223	CcSEcCtD
Mefloquine—Insomnia—Capecitabine—breast cancer	2.42e-05	0.000221	CcSEcCtD
Mefloquine—Rash—Fluorouracil—breast cancer	2.41e-05	0.000221	CcSEcCtD
Mefloquine—Dermatitis—Fluorouracil—breast cancer	2.41e-05	0.000221	CcSEcCtD
Mefloquine—Paraesthesia—Capecitabine—breast cancer	2.4e-05	0.00022	CcSEcCtD
Mefloquine—Decreased appetite—Docetaxel—breast cancer	2.4e-05	0.00022	CcSEcCtD
Mefloquine—Hypersensitivity—Paclitaxel—breast cancer	2.4e-05	0.00022	CcSEcCtD
Mefloquine—Headache—Fluorouracil—breast cancer	2.4e-05	0.00022	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Docetaxel—breast cancer	2.39e-05	0.000218	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—breast cancer	2.39e-05	0.000218	CcSEcCtD
Mefloquine—Dyspnoea—Capecitabine—breast cancer	2.39e-05	0.000218	CcSEcCtD
Mefloquine—Fatigue—Docetaxel—breast cancer	2.38e-05	0.000218	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—breast cancer	2.38e-05	0.000218	CcSEcCtD
Mefloquine—Nausea—Irinotecan—breast cancer	2.38e-05	0.000217	CcSEcCtD
Mefloquine—Nausea—Mitoxantrone—breast cancer	2.38e-05	0.000217	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—breast cancer	2.36e-05	0.000216	CcSEcCtD
Mefloquine—Dyspepsia—Capecitabine—breast cancer	2.36e-05	0.000216	CcSEcCtD
Mefloquine—Chills—Epirubicin—breast cancer	2.35e-05	0.000215	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—breast cancer	2.34e-05	0.000214	CcSEcCtD
Mefloquine—Asthenia—Paclitaxel—breast cancer	2.34e-05	0.000214	CcSEcCtD
Mefloquine—Decreased appetite—Capecitabine—breast cancer	2.33e-05	0.000213	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—breast cancer	2.32e-05	0.000212	CcSEcCtD
Mefloquine—Nausea—Gemcitabine—breast cancer	2.31e-05	0.000212	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Capecitabine—breast cancer	2.31e-05	0.000211	CcSEcCtD
Mefloquine—Fatigue—Capecitabine—breast cancer	2.31e-05	0.000211	CcSEcCtD
Mefloquine—Pruritus—Paclitaxel—breast cancer	2.31e-05	0.000211	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—breast cancer	2.3e-05	0.000211	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—breast cancer	2.3e-05	0.00021	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—breast cancer	2.3e-05	0.00021	CcSEcCtD
Mefloquine—Erythema—Epirubicin—breast cancer	2.28e-05	0.000209	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—breast cancer	2.28e-05	0.000209	CcSEcCtD
Mefloquine—Feeling abnormal—Docetaxel—breast cancer	2.28e-05	0.000208	CcSEcCtD
Mefloquine—Nausea—Fluorouracil—breast cancer	2.27e-05	0.000208	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—breast cancer	2.27e-05	0.000208	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—breast cancer	2.26e-05	0.000207	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—breast cancer	2.26e-05	0.000207	CcSEcCtD
Mefloquine—Gastrointestinal pain—Docetaxel—breast cancer	2.26e-05	0.000207	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—breast cancer	2.25e-05	0.000206	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—breast cancer	2.25e-05	0.000206	CcSEcCtD
Mefloquine—Diarrhoea—Paclitaxel—breast cancer	2.23e-05	0.000204	CcSEcCtD
Mefloquine—Feeling abnormal—Capecitabine—breast cancer	2.21e-05	0.000202	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—breast cancer	2.2e-05	0.000202	CcSEcCtD
Mefloquine—Malaise—Methotrexate—breast cancer	2.2e-05	0.000201	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—breast cancer	2.2e-05	0.000201	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—breast cancer	2.19e-05	0.000201	CcSEcCtD
Mefloquine—Gastrointestinal pain—Capecitabine—breast cancer	2.19e-05	0.0002	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—breast cancer	2.19e-05	0.0002	CcSEcCtD
Mefloquine—Abdominal pain—Docetaxel—breast cancer	2.19e-05	0.0002	CcSEcCtD
Mefloquine—Body temperature increased—Docetaxel—breast cancer	2.19e-05	0.0002	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—breast cancer	2.18e-05	0.0002	CcSEcCtD
Mefloquine—Chills—Doxorubicin—breast cancer	2.18e-05	0.000199	CcSEcCtD
Mefloquine—Dizziness—Paclitaxel—breast cancer	2.16e-05	0.000197	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—breast cancer	2.15e-05	0.000197	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—breast cancer	2.15e-05	0.000196	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—breast cancer	2.13e-05	0.000195	CcSEcCtD
Mefloquine—Urticaria—Capecitabine—breast cancer	2.13e-05	0.000195	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—breast cancer	2.12e-05	0.000194	CcSEcCtD
Mefloquine—Abdominal pain—Capecitabine—breast cancer	2.12e-05	0.000194	CcSEcCtD
Mefloquine—Body temperature increased—Capecitabine—breast cancer	2.12e-05	0.000194	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—breast cancer	2.11e-05	0.000194	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—breast cancer	2.11e-05	0.000193	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—breast cancer	2.11e-05	0.000193	CcSEcCtD
Mefloquine—Agitation—Epirubicin—breast cancer	2.1e-05	0.000192	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—breast cancer	2.08e-05	0.00019	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—breast cancer	2.08e-05	0.00019	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—breast cancer	2.08e-05	0.00019	CcSEcCtD
Mefloquine—Vomiting—Paclitaxel—breast cancer	2.07e-05	0.00019	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.06e-05	0.000189	CcSEcCtD
Mefloquine—Malaise—Epirubicin—breast cancer	2.06e-05	0.000189	CcSEcCtD
Mefloquine—Rash—Paclitaxel—breast cancer	2.06e-05	0.000188	CcSEcCtD
Mefloquine—Dermatitis—Paclitaxel—breast cancer	2.05e-05	0.000188	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—breast cancer	2.05e-05	0.000188	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—breast cancer	2.05e-05	0.000188	CcSEcCtD
Mefloquine—Syncope—Epirubicin—breast cancer	2.05e-05	0.000187	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—breast cancer	2.04e-05	0.000187	CcSEcCtD
Mefloquine—Headache—Paclitaxel—breast cancer	2.04e-05	0.000187	CcSEcCtD
Mefloquine—Hypersensitivity—Docetaxel—breast cancer	2.04e-05	0.000186	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—breast cancer	2.03e-05	0.000186	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—breast cancer	2.02e-05	0.000185	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—breast cancer	2.01e-05	0.000184	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—breast cancer	2.01e-05	0.000184	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—breast cancer	1.99e-05	0.000182	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—breast cancer	1.99e-05	0.000182	CcSEcCtD
Mefloquine—Asthenia—Docetaxel—breast cancer	1.98e-05	0.000181	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—breast cancer	1.98e-05	0.000181	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—breast cancer	1.97e-05	0.00018	CcSEcCtD
Mefloquine—Hypersensitivity—Capecitabine—breast cancer	1.97e-05	0.00018	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—breast cancer	1.96e-05	0.000179	CcSEcCtD
Mefloquine—Pruritus—Docetaxel—breast cancer	1.96e-05	0.000179	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—breast cancer	1.95e-05	0.000179	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—breast cancer	1.95e-05	0.000178	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—breast cancer	1.94e-05	0.000178	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—breast cancer	1.94e-05	0.000178	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—breast cancer	1.94e-05	0.000178	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—breast cancer	1.94e-05	0.000178	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—breast cancer	1.94e-05	0.000177	CcSEcCtD
Mefloquine—Nausea—Paclitaxel—breast cancer	1.94e-05	0.000177	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—breast cancer	1.94e-05	0.000177	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.93e-05	0.000177	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—breast cancer	1.93e-05	0.000176	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—breast cancer	1.92e-05	0.000176	CcSEcCtD
Mefloquine—Asthenia—Capecitabine—breast cancer	1.92e-05	0.000176	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—breast cancer	1.91e-05	0.000174	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—breast cancer	1.9e-05	0.000174	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—breast cancer	1.9e-05	0.000173	CcSEcCtD
Mefloquine—Pruritus—Capecitabine—breast cancer	1.89e-05	0.000173	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—breast cancer	1.89e-05	0.000173	CcSEcCtD
Mefloquine—Diarrhoea—Docetaxel—breast cancer	1.89e-05	0.000173	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—breast cancer	1.88e-05	0.000172	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—breast cancer	1.87e-05	0.000171	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—breast cancer	1.86e-05	0.000171	CcSEcCtD
Mefloquine—Oedema—Epirubicin—breast cancer	1.86e-05	0.000171	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—breast cancer	1.86e-05	0.00017	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—breast cancer	1.86e-05	0.00017	CcSEcCtD
Mefloquine—Shock—Epirubicin—breast cancer	1.83e-05	0.000168	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—breast cancer	1.83e-05	0.000168	CcSEcCtD
Mefloquine—Diarrhoea—Capecitabine—breast cancer	1.83e-05	0.000168	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—breast cancer	1.83e-05	0.000167	CcSEcCtD
Mefloquine—Dizziness—Docetaxel—breast cancer	1.83e-05	0.000167	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—breast cancer	1.83e-05	0.000167	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—breast cancer	1.82e-05	0.000167	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—breast cancer	1.82e-05	0.000167	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—breast cancer	1.82e-05	0.000166	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—breast cancer	1.81e-05	0.000166	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—breast cancer	1.8e-05	0.000165	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—breast cancer	1.8e-05	0.000165	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—breast cancer	1.8e-05	0.000165	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—breast cancer	1.8e-05	0.000165	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—breast cancer	1.8e-05	0.000165	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—breast cancer	1.79e-05	0.000164	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—breast cancer	1.79e-05	0.000164	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.79e-05	0.000164	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—breast cancer	1.78e-05	0.000163	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—breast cancer	1.78e-05	0.000163	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—breast cancer	1.77e-05	0.000162	CcSEcCtD
Mefloquine—Dizziness—Capecitabine—breast cancer	1.77e-05	0.000162	CcSEcCtD
Mefloquine—Vomiting—Docetaxel—breast cancer	1.76e-05	0.000161	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—breast cancer	1.75e-05	0.00016	CcSEcCtD
Mefloquine—Rash—Docetaxel—breast cancer	1.74e-05	0.000159	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—breast cancer	1.74e-05	0.000159	CcSEcCtD
Mefloquine—Dermatitis—Docetaxel—breast cancer	1.74e-05	0.000159	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—breast cancer	1.74e-05	0.000159	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—breast cancer	1.73e-05	0.000158	CcSEcCtD
Mefloquine—Headache—Docetaxel—breast cancer	1.73e-05	0.000158	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—breast cancer	1.73e-05	0.000158	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—breast cancer	1.73e-05	0.000158	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—breast cancer	1.72e-05	0.000157	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—breast cancer	1.72e-05	0.000157	CcSEcCtD
Mefloquine—Vomiting—Capecitabine—breast cancer	1.7e-05	0.000156	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—breast cancer	1.7e-05	0.000155	CcSEcCtD
Mefloquine—Shock—Doxorubicin—breast cancer	1.7e-05	0.000155	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—breast cancer	1.69e-05	0.000155	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—breast cancer	1.69e-05	0.000155	CcSEcCtD
Mefloquine—Rash—Capecitabine—breast cancer	1.69e-05	0.000154	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—breast cancer	1.69e-05	0.000154	CcSEcCtD
Mefloquine—Dermatitis—Capecitabine—breast cancer	1.69e-05	0.000154	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—breast cancer	1.68e-05	0.000154	CcSEcCtD
Mefloquine—Headache—Capecitabine—breast cancer	1.68e-05	0.000153	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—breast cancer	1.68e-05	0.000153	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—breast cancer	1.67e-05	0.000153	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—breast cancer	1.67e-05	0.000153	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—breast cancer	1.66e-05	0.000152	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—breast cancer	1.66e-05	0.000152	CcSEcCtD
Mefloquine—Nausea—Docetaxel—breast cancer	1.64e-05	0.00015	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—breast cancer	1.64e-05	0.00015	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—breast cancer	1.64e-05	0.00015	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—breast cancer	1.63e-05	0.000149	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—breast cancer	1.62e-05	0.000148	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—breast cancer	1.61e-05	0.000148	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—breast cancer	1.61e-05	0.000147	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—breast cancer	1.61e-05	0.000147	CcSEcCtD
Mefloquine—Nausea—Capecitabine—breast cancer	1.59e-05	0.000145	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—breast cancer	1.58e-05	0.000145	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—breast cancer	1.57e-05	0.000144	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—breast cancer	1.57e-05	0.000144	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.57e-05	0.000144	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—breast cancer	1.56e-05	0.000143	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—breast cancer	1.55e-05	0.000142	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—breast cancer	1.54e-05	0.000141	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—breast cancer	1.54e-05	0.000141	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—breast cancer	1.53e-05	0.00014	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—breast cancer	1.52e-05	0.00014	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—breast cancer	1.52e-05	0.000139	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—breast cancer	1.5e-05	0.000137	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—breast cancer	1.49e-05	0.000136	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—breast cancer	1.49e-05	0.000136	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—breast cancer	1.48e-05	0.000136	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—breast cancer	1.47e-05	0.000135	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—breast cancer	1.47e-05	0.000135	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—breast cancer	1.47e-05	0.000134	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—breast cancer	1.43e-05	0.000131	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—breast cancer	1.42e-05	0.00013	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—breast cancer	1.41e-05	0.000129	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—breast cancer	1.41e-05	0.000129	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—breast cancer	1.37e-05	0.000126	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—breast cancer	1.37e-05	0.000125	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—breast cancer	1.36e-05	0.000125	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—breast cancer	1.36e-05	0.000125	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—breast cancer	1.36e-05	0.000125	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—breast cancer	1.34e-05	0.000122	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—breast cancer	1.32e-05	0.000121	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—breast cancer	1.32e-05	0.000121	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—breast cancer	1.28e-05	0.000117	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—breast cancer	1.27e-05	0.000116	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—breast cancer	1.27e-05	0.000116	CcSEcCtD
Mefloquine—Rash—Methotrexate—breast cancer	1.26e-05	0.000115	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—breast cancer	1.25e-05	0.000115	CcSEcCtD
Mefloquine—Headache—Methotrexate—breast cancer	1.25e-05	0.000114	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—breast cancer	1.24e-05	0.000113	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—breast cancer	1.23e-05	0.000113	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—breast cancer	1.22e-05	0.000112	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—breast cancer	1.19e-05	0.000108	CcSEcCtD
Mefloquine—Nausea—Methotrexate—breast cancer	1.18e-05	0.000108	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—breast cancer	1.18e-05	0.000108	CcSEcCtD
Mefloquine—Rash—Epirubicin—breast cancer	1.18e-05	0.000108	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—breast cancer	1.17e-05	0.000107	CcSEcCtD
Mefloquine—Headache—Epirubicin—breast cancer	1.17e-05	0.000107	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—breast cancer	1.14e-05	0.000104	CcSEcCtD
Mefloquine—Nausea—Epirubicin—breast cancer	1.11e-05	0.000101	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—breast cancer	1.1e-05	0.0001	CcSEcCtD
Mefloquine—Rash—Doxorubicin—breast cancer	1.09e-05	9.95e-05	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—breast cancer	1.09e-05	9.94e-05	CcSEcCtD
Mefloquine—Headache—Doxorubicin—breast cancer	1.08e-05	9.89e-05	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—breast cancer	1.02e-05	9.38e-05	CcSEcCtD
Mefloquine—ABCB1—Metabolism—HBA1—breast cancer	2.46e-06	3.41e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA3—breast cancer	2.44e-06	3.39e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.44e-06	3.38e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC2A2—breast cancer	2.43e-06	3.36e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—breast cancer	2.42e-06	3.36e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—breast cancer	2.42e-06	3.36e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FHL2—breast cancer	2.41e-06	3.34e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NME1—breast cancer	2.41e-06	3.34e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PHGDH—breast cancer	2.41e-06	3.34e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ADSL—breast cancer	2.41e-06	3.34e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UMPS—breast cancer	2.41e-06	3.34e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—breast cancer	2.4e-06	3.33e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CD—breast cancer	2.4e-06	3.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—breast cancer	2.4e-06	3.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ACHE—breast cancer	2.4e-06	3.33e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CG—breast cancer	2.4e-06	3.32e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCG2—breast cancer	2.38e-06	3.3e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTR—breast cancer	2.38e-06	3.3e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CPT1A—breast cancer	2.38e-06	3.3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—breast cancer	2.38e-06	3.3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SERPINE1—breast cancer	2.37e-06	3.29e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—BRIP1—breast cancer	2.37e-06	3.28e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—LDHB—breast cancer	2.37e-06	3.28e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPSE—breast cancer	2.37e-06	3.28e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—breast cancer	2.35e-06	3.26e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—breast cancer	2.35e-06	3.26e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—breast cancer	2.35e-06	3.25e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—breast cancer	2.34e-06	3.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HPGDS—breast cancer	2.33e-06	3.23e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	2.33e-06	3.23e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CG—breast cancer	2.33e-06	3.23e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HBA1—breast cancer	2.32e-06	3.21e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CD—breast cancer	2.29e-06	3.18e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK8—breast cancer	2.29e-06	3.18e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—breast cancer	2.28e-06	3.17e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP17A1—breast cancer	2.27e-06	3.15e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOS3—breast cancer	2.27e-06	3.14e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ALB—breast cancer	2.26e-06	3.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—breast cancer	2.26e-06	3.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ACHE—breast cancer	2.26e-06	3.14e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO1—breast cancer	2.25e-06	3.12e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS1—breast cancer	2.25e-06	3.12e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCC1—breast cancer	2.24e-06	3.11e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA3—breast cancer	2.24e-06	3.11e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HMMR—breast cancer	2.24e-06	3.11e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2D6—breast cancer	2.2e-06	3.06e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPARGC1B—breast cancer	2.17e-06	3.01e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—breast cancer	2.17e-06	3.01e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NOS3—breast cancer	2.16e-06	3e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA2—breast cancer	2.16e-06	3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—breast cancer	2.16e-06	2.99e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—breast cancer	2.15e-06	2.98e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RAF1—breast cancer	2.14e-06	2.97e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP17A1—breast cancer	2.14e-06	2.97e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RELA—breast cancer	2.13e-06	2.96e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—breast cancer	2.12e-06	2.94e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS1—breast cancer	2.12e-06	2.94e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO1—breast cancer	2.12e-06	2.94e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—breast cancer	2.11e-06	2.93e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CD—breast cancer	2.11e-06	2.92e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	2.1e-06	2.92e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—FASN—breast cancer	2.1e-06	2.91e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—breast cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MTOR—breast cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CB—breast cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—BCHE—breast cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALB—breast cancer	2.08e-06	2.88e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A5—breast cancer	2.06e-06	2.86e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA4—breast cancer	2.05e-06	2.84e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA9—breast cancer	2.05e-06	2.84e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CD—breast cancer	2.04e-06	2.84e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA2—breast cancer	2.04e-06	2.83e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALB—breast cancer	2.02e-06	2.8e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—breast cancer	2.01e-06	2.79e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK3—breast cancer	2e-06	2.77e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA2—breast cancer	2e-06	2.77e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX2—breast cancer	2e-06	2.77e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CB—breast cancer	2e-06	2.77e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—breast cancer	2e-06	2.77e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NQO1—breast cancer	1.99e-06	2.77e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC2A1—breast cancer	1.99e-06	2.77e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NOS3—breast cancer	1.99e-06	2.76e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—breast cancer	1.98e-06	2.74e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—FASN—breast cancer	1.98e-06	2.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX4—breast cancer	1.97e-06	2.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SULT1A1—breast cancer	1.97e-06	2.74e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—BCHE—breast cancer	1.97e-06	2.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—breast cancer	1.96e-06	2.72e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A5—breast cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—breast cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP3A4—breast cancer	1.94e-06	2.7e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—breast cancer	1.94e-06	2.69e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFB1—breast cancer	1.94e-06	2.69e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NOS3—breast cancer	1.93e-06	2.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—IDH1—breast cancer	1.93e-06	2.67e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA1—breast cancer	1.93e-06	2.67e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CASP3—breast cancer	1.92e-06	2.67e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—breast cancer	1.92e-06	2.66e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1B1—breast cancer	1.91e-06	2.65e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—breast cancer	1.91e-06	2.65e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NAT2—breast cancer	1.91e-06	2.64e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—breast cancer	1.9e-06	2.64e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	1.9e-06	2.64e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC2A1—breast cancer	1.88e-06	2.61e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NQO1—breast cancer	1.88e-06	2.61e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HSP90AA1—breast cancer	1.87e-06	2.6e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—breast cancer	1.87e-06	2.6e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—breast cancer	1.87e-06	2.59e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—breast cancer	1.85e-06	2.57e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CB—breast cancer	1.84e-06	2.55e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP3A4—breast cancer	1.83e-06	2.54e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA1—breast cancer	1.82e-06	2.53e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—breast cancer	1.82e-06	2.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—breast cancer	1.82e-06	2.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—breast cancer	1.81e-06	2.51e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—breast cancer	1.81e-06	2.51e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1B1—breast cancer	1.8e-06	2.5e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—STK11—breast cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP19A1—breast cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—breast cancer	1.8e-06	2.49e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CB—breast cancer	1.78e-06	2.47e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK8—breast cancer	1.77e-06	2.45e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HSP90AA1—breast cancer	1.77e-06	2.45e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—breast cancer	1.77e-06	2.45e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—breast cancer	1.76e-06	2.44e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—breast cancer	1.73e-06	2.39e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA1—breast cancer	1.72e-06	2.38e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—STK11—breast cancer	1.69e-06	2.35e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP19A1—breast cancer	1.69e-06	2.35e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—breast cancer	1.68e-06	2.32e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MED12—breast cancer	1.67e-06	2.32e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—DPYD—breast cancer	1.67e-06	2.32e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—COMT—breast cancer	1.67e-06	2.32e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—breast cancer	1.66e-06	2.31e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—breast cancer	1.65e-06	2.29e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALDOA—breast cancer	1.65e-06	2.28e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HMOX1—breast cancer	1.64e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ITPR1—breast cancer	1.64e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—breast cancer	1.63e-06	2.26e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—breast cancer	1.62e-06	2.24e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA3—breast cancer	1.6e-06	2.22e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—breast cancer	1.6e-06	2.22e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC2A2—breast cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—breast cancer	1.59e-06	2.2e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—COMT—breast cancer	1.57e-06	2.18e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—breast cancer	1.57e-06	2.17e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CPT1A—breast cancer	1.55e-06	2.16e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTR—breast cancer	1.55e-06	2.16e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCG2—breast cancer	1.55e-06	2.16e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMS—breast cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HMOX1—breast cancer	1.55e-06	2.14e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK3—breast cancer	1.54e-06	2.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ITPR1—breast cancer	1.54e-06	2.14e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—breast cancer	1.54e-06	2.14e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PLA2G4A—breast cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOR1—breast cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—breast cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—breast cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPGDS—breast cancer	1.52e-06	2.11e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HBA1—breast cancer	1.51e-06	2.1e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—breast cancer	1.5e-06	2.08e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFB1—breast cancer	1.5e-06	2.08e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—breast cancer	1.48e-06	2.06e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—breast cancer	1.48e-06	2.05e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ACHE—breast cancer	1.48e-06	2.05e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—breast cancer	1.47e-06	2.04e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GPX1—breast cancer	1.46e-06	2.03e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—breast cancer	1.46e-06	2.03e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMS—breast cancer	1.46e-06	2.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1A1—breast cancer	1.45e-06	2.01e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PLA2G4A—breast cancer	1.44e-06	2e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—breast cancer	1.44e-06	2e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOR1—breast cancer	1.44e-06	2e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ERCC2—breast cancer	1.44e-06	1.99e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP17A1—breast cancer	1.4e-06	1.94e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—breast cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO1—breast cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS1—breast cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GPX1—breast cancer	1.38e-06	1.91e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1A1—breast cancer	1.37e-06	1.89e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2D6—breast cancer	1.36e-06	1.88e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ERCC2—breast cancer	1.35e-06	1.88e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTHFR—breast cancer	1.35e-06	1.87e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—breast cancer	1.35e-06	1.87e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA2—breast cancer	1.33e-06	1.85e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FASN—breast cancer	1.29e-06	1.79e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—BCHE—breast cancer	1.29e-06	1.79e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—breast cancer	1.27e-06	1.77e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTHFR—breast cancer	1.27e-06	1.77e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A5—breast cancer	1.27e-06	1.76e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CAV1—breast cancer	1.25e-06	1.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—breast cancer	1.23e-06	1.71e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NQO1—breast cancer	1.23e-06	1.7e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC2A1—breast cancer	1.23e-06	1.7e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—breast cancer	1.22e-06	1.69e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—breast cancer	1.18e-06	1.64e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1B1—breast cancer	1.18e-06	1.63e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CAV1—breast cancer	1.17e-06	1.63e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CG—breast cancer	1.13e-06	1.57e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—breast cancer	1.13e-06	1.57e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA1—breast cancer	1.12e-06	1.56e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—breast cancer	1.12e-06	1.55e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—STK11—breast cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP19A1—breast cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—breast cancer	1.09e-06	1.51e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CG—breast cancer	1.07e-06	1.48e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—breast cancer	1.04e-06	1.44e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—COMT—breast cancer	1.03e-06	1.43e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—breast cancer	1.02e-06	1.42e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HMOX1—breast cancer	1.01e-06	1.4e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ITPR1—breast cancer	1.01e-06	1.4e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CD—breast cancer	9.98e-07	1.38e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—breast cancer	9.95e-07	1.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALB—breast cancer	9.85e-07	1.37e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—breast cancer	9.7e-07	1.35e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMS—breast cancer	9.53e-07	1.32e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NOS3—breast cancer	9.42e-07	1.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOR1—breast cancer	9.42e-07	1.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PLA2G4A—breast cancer	9.42e-07	1.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—breast cancer	9.42e-07	1.31e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CD—breast cancer	9.4e-07	1.3e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALB—breast cancer	9.28e-07	1.29e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—breast cancer	9.14e-07	1.27e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GPX1—breast cancer	9.02e-07	1.25e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1A1—breast cancer	8.93e-07	1.24e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NOS3—breast cancer	8.88e-07	1.23e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—breast cancer	8.87e-07	1.23e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ERCC2—breast cancer	8.85e-07	1.23e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CB—breast cancer	8.7e-07	1.21e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—breast cancer	8.62e-07	1.19e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTHFR—breast cancer	8.32e-07	1.15e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CB—breast cancer	8.19e-07	1.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—breast cancer	8.12e-07	1.13e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CAV1—breast cancer	7.68e-07	1.06e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—breast cancer	7.51e-07	1.04e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—breast cancer	7.08e-07	9.82e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CG—breast cancer	6.99e-07	9.7e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CD—breast cancer	6.15e-07	8.52e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALB—breast cancer	6.07e-07	8.41e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NOS3—breast cancer	5.8e-07	8.05e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CB—breast cancer	5.36e-07	7.43e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—breast cancer	5.31e-07	7.36e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—breast cancer	5.3e-07	7.35e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—breast cancer	5e-07	6.93e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—breast cancer	4.63e-07	6.42e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—breast cancer	4.33e-07	6.01e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—breast cancer	4.08e-07	5.66e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—breast cancer	3.27e-07	4.53e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—breast cancer	2.67e-07	3.7e-06	CbGpPWpGaD
